Our Research
Advancing the science of infectious disease treatment and diagnosis
Current Research Focus
Novel Antifungal Compounds
Our team is exploring new classes of antifungal compounds that target cell wall components unique to pathogenic fungi. This approach allows for highly selective targeting with minimal impact on human cells.
Current projects include:
- Development of chitin synthase inhibitors for treatment of invasive aspergillosis
- Investigation of ergosterol biosynthesis disruptors with improved safety profiles
- Identification of novel targets in resistant Candida species
C. difficile Microbiome-Sparing Therapies
Our C. difficile research focuses on developing treatments that specifically target C. difficile while preserving the protective gut microbiome. This approach aims to reduce the high recurrence rates associated with current treatment options.
Key research directions include:
- Bacteriophage-based therapies specifically targeting C. difficile
- Narrow-spectrum antimicrobials with high selectivity for C. difficile
- Toxin-neutralizing compounds that prevent disease progression without affecting bacterial growth
Rapid Diagnostic Technologies
Our diagnostic research program is developing next-generation technologies for rapid identification of pathogens and antimicrobial resistance markers directly from clinical samples.
Current research includes:
- CRISPR-based detection systems for fungal pathogens
- Machine learning algorithms for interpretation of complex microbiological data
- Portable biosensors for point-of-care diagnosis in resource-limited settings
Precision Antimicrobial Dosing
Our therapeutic drug monitoring research aims to optimize antimicrobial dosing through better understanding of pharmacokinetics in diverse patient populations.
Key projects include:
- Development of novel biomarkers for antimicrobial activity and toxicity
- Creation of machine learning models to predict drug concentrations based on minimal sampling
- Investigation of tissue-specific drug penetration in difficult-to-treat infections
Publications and Presentations
Our team regularly publishes in peer-reviewed journals and presents at major scientific conferences. Recent publications include:
-
Novel chitin synthase inhibitors show promising activity against Aspergillus fumigatus in vitro and in murine models
Journal of Antimicrobial Chemotherapy, 2024
-
CRISPR-Cas12-based rapid detection of invasive fungal pathogens from blood samples
Nature Biotechnology, 2023
-
Machine learning approaches improve prediction of vancomycin trough concentrations in critically ill patients
Clinical Pharmacology & Therapeutics, 2023
Collaborate on Research
Interface Laboratories welcomes research collaborations with academic institutions, healthcare organizations, and industry partners.
Contact Our Research Team